Results 211 to 220 of about 385,065 (234)

Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen.

The Journal of Immunology, 1994
Ag-pulsed B cells are potent APCs, in part, because of the ability of the Ig receptor to mediate rapid and specific Ag uptake. However, it is also known that full T cell activation requires signals delivered by costimulatory molecules, which naive B ...
D. Lenschow, Anne I. Sperling, Michael P. Cooke, G. Freeman, Lesley Rhee, D. Decker, Gary S. Gray, Lee M. Nadler, Christopher C. Goodnow, J. Bluestone   +9 more
semanticscholar   +3 more sources

Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.

The Journal of Immunology, 1998
We have previously shown that B7-2 (CD86)-transfected P815 tumor cells elicit tumor-eradicating immunity that leads to the regression of the B7-2+ P815 tumor after transient growth in normal DBA/2 mice.
R. N. La Motte, A. Sharpe, J. Bluestone, M. Mokyr   +3 more
semanticscholar   +3 more sources

Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.

The Journal of Immunology, 1998
The differentiation of CD4+ T cells into a Th1 vs Th2 phenotype profoundly influences the outcome of autoimmune and infectious diseases. B7 costimulation has been shown to affect the production of both Th1 and Th2 cytokines, depending on the system ...
Schweitzer An, Arlene H. Sharpe
semanticscholar   +3 more sources

Interferon‐γ and interleukin‐10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7‐1) expression

European Journal of Immunology, 1996
AbstractCD80(B7‐1) and CD86(B7‐2) co‐stimulatory molecules have been reported to activate Th1/Th2 development pathways differentially. It is well known that Langerhans cells (LC), potent antigen‐presenting dendritic cells in the epidermis, express several co‐stimulatory molecules and that this expression is modulated by several cytokines.
H. Ozawa, S. Aiba, S. Nakagawa, H. Tagami   +3 more
semanticscholar   +3 more sources

Targeting B7‐1 in immunotherapy

Medicinal research reviews (Print), 2020
Modulation of T‐cell immune functions by blocking key immune checkpoint protein interactions using monoclonal antibodies (mAbs) has been an innovative immunotherapeutic strategy. T‐cells are regulated by different checkpoint proteins at the immunological
Rui Chen, A. Ganesan, Isobel S Okoye, E. Arutyunova, S. Elahi, M. J. Lemieux, K. Barakat   +6 more
semanticscholar   +1 more source

The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen.

Immunity, 1994
T cell tolerance to peripheral antigens is believed to result mainly from the inability of parenchymal cells to present antigens in an immunogenic form due to the lack of expression of T cell costimulator. We found, however, that transgenic expression of the T cell costimulator B7-1 on the islets of Langerhans is not sufficient to abolish the in vivo ...
Sylvie Guarder, Sylvie Guarder, Jeffrey Meyerhoff, R. A. Flavell, R. A. Flavell   +4 more
semanticscholar   +3 more sources

Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression

Cancer Immunology, Immunotherapy, 2000
The aim of this study was to compare the antigenicity of human melanoma cells molecularly modified by particle-mediated gene transfer to have transient or stable expression of the B7-1 co-stimulatory molecule (CD80). The unmodified melanoma cells (mel5, m21) had no constitutive expression of B7-1, but 22%-28% of cells had transient B7-1 expression 24 h
McCarthy, Donna O., Glowacki, Nicole, Schell, Kathleen, Emler, Carol A., Albertini, Mark R.   +4 more
openaire   +3 more sources

Complete amino acid sequence of a papain-solubilized human histocompatibility antigen HLA-B7. 1. Isolation and amino acid composition of fragments and of tryptic and chymotryptic peptides.

Biochemistry, 1979
As a part of the overall strategy for determining the complete covalent structure of the papain-solubilized portion of the heavy chain of the human histocompatibility antigen HLA-B7, the protein was dissected into various fragments by a combination of partial acid hydrolysis and cyanogen bromide cleavage.
J. A. López de Castro, H. Orr, R. Robb, T. Kostyk, D. Mann, J. Strominger   +5 more
semanticscholar   +3 more sources

A Leishmania protein that modulates interleukin (IL)‐12, IL‐10 and tumor necrosis factor‐α production and expression of B7‐1 in human monocyte‐derived antigen‐presenting cells

European Journal of Immunology, 1997
AbstractLeIF, a gene homologue of the eukaryotic initiation factor 4A was first described as a leishmanial antigen that induced a Th1‐type T cell response in peripheral blood mononuclear cells (PBMC) from leishmaniasis patients. Moreover, the interferon (IFN)‐γ production by PBMC was found to be interleukin (IL)‐12 dependent.
P. Probst, Y. Skeiky, Michelle Steeves, A. Gervassi, K. Grabstein, S. Reed   +5 more
semanticscholar   +3 more sources

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1

Journal of Immunological Methods, 2003
The ELISPOT assay is used to detect T-cell responses in patients enrolled in vaccine clinical trials; it is a relatively sensitive assay that can be performed without in vitro stimulation (IVS) of PBMC. However, this assay may be limited in some cases because of a weak signal 1 (as is the case for tumor-associated antigens [TAA]), or by a limited ...
Philip M, Arlen, James L, Gulley, Claudia, Palena, John, Marshall, Jeffrey, Schlom, Kwong Yok, Tsang   +5 more
openaire   +2 more sources